Genetic testing pitfalls: choosing between panels and exomes

Subsequent whole exome sequencing added 18 diagnoses, increasing the overall yield of the sequential strategy to approximately 58%. The result is clinically useful but not decisive: a panel can perform well in a defined phenotype, while still missing pathogenic variants outside its design boundaries.

The comparison between exome sequencing and panel testing for pediatric immunodeficiency is therefore not a contest between a narrow test and a superior universal test. It is a selection problem. The relevant variables are phenotype specificity, gene coverage, variant class, read depth, interpretation capacity, turnaround time, and the clinical consequences of an inconclusive result.

More than 400 monogenic inborn errors of immunity have been defined. Their presentations overlap. Severe infections, persistent viral disease, unusual organisms, autoimmunity, inflammatory syndromes, cytopenias, and poor vaccine responses can arise from different molecular mechanisms. A diagnostic assay that is efficient for one phenotype can be poorly matched to another.

A high read depth cannot compensate for an incomplete gene list, and a broad gene list cannot compensate for poor clinical interpretation.

The diagnostic problem: more than 400 disorders, overlapping phenotypes

Pediatric immune deficiency is genetically heterogeneous. The same clinical pattern may result from defects in signaling, lymphocyte development, antibody production, complement activity, phagocyte function, or immune regulation. Conversely, a single pathogenic gene can produce several phenotypes depending on the variant, inheritance pattern, residual protein function, age, and environmental exposures.

This creates two different sources of diagnostic error:

1. The assay does not examine the relevant locus or variant class.

2. The assay detects a variant, but the laboratory cannot classify it with sufficient confidence.

Targeted panels address the first problem by concentrating sequencing capacity on a selected set of genes. This usually enables high analytical depth and more consistent coverage across coding exons and splice-adjacent regions. The approach is technically efficient when the phenotype strongly indicates a limited group of disorders.

WES addresses a different problem. It examines the protein-coding regions of the genome, known as the exome. These regions represent approximately 1% of the human genome but contain about 85% of known disease-causing variants. WES therefore expands the search space without requiring a separate assay for every candidate gene.

Neither platform examines all clinically relevant variation. WES has limited performance for deep intronic variants, regulatory variants, repeat expansions, some structural rearrangements, complex copy number changes, low-level mosaicism, and regions with poor sequenceability. A negative WES result is not equivalent to the absence of a genetic cause.

Phenotype specificity determines the value of breadth

A targeted panel is most defensible when the clinical phenotype has high discriminatory value. Examples include a well-defined pattern of recurrent bacterial infections with abnormal immunoglobulin production, a persistent neutropenia phenotype with supporting laboratory findings, or a combined immunodeficiency pattern supported by lymphocyte subset abnormalities and abnormal functional assays.

A broader assay becomes more useful when the phenotype is atypical, incomplete, or internally inconsistent. This includes cases in which:

• infection history does not map cleanly to one immune compartment;
• autoimmunity or autoinflammation dominates the presentation;
• laboratory findings suggest more than one mechanism;
• the child has features spanning immune deficiency and immune dysregulation;
• the suspected diagnosis is not represented by a single established gene;
• an initial targeted test is negative despite strong clinical evidence.

The practical distinction is not simply panel versus WES. It is hypothesis-driven testing versus hypothesis-expanding testing.

Performance metrics: targeted panels versus WES

The most visible metric is diagnostic yield. It is also the easiest metric to misuse. Yield depends on referral criteria, disease prevalence, inclusion of syndromic cases, sequencing platform, variant interpretation rules, family structure, and whether the cohort was enriched for patients with previous negative testing.

In the longitudinal cohort covering 2010–2020, targeted panel sequencing identified a diagnosis in 433 of 780 patients, corresponding to a 56% diagnostic rate. WES performed after the panel added 18 diagnoses. The combined sequential approach reached approximately 58% in that cohort.

A separate WES-only pipeline for 98 patients with atypical suspected primary immunodeficiency reported a 45% diagnostic yield. That figure should not be directly compared with the 56% panel yield as if the assays were tested in identical populations. The cohorts differed in phenotype composition and likely in pretest probability. Atypical cases are intrinsically harder to classify.

Coverage is not the same as diagnostic sensitivity

Laboratory reports often present coverage statistics, but those values require interpretation. A panel may report near-complete coverage of the selected coding regions. That is useful only if the relevant pathogenic variant is within those regions and detectable by the assay’s chemistry and bioinformatic pipeline.

WES may provide broader theoretical coverage but lower uniformity in technically difficult exons. A gene can be included in the test while still containing poorly covered regions. The clinical question is therefore not whether a gene appears on the report. It is whether the relevant sequence and variant class were adequately interrogated.

Analytical sensitivity also varies by variant type:

• Single-nucleotide variants and small insertions or deletions are generally the core strength of both panel sequencing and WES.
• Copy number variants may be detected by some pipelines but require validation and may not be captured consistently.
• Structural variants can be missed or incompletely characterized by exome-based methods.
• Deep intronic and regulatory variants are usually outside the principal WES target.
• Mosaic variants may require sufficient read depth, appropriate allele-frequency thresholds, and dedicated interpretation.
• Repeat-rich or homologous regions can produce alignment and calling limitations.

This is why a negative result must be read against the technical limitations section, not only the conclusion line.

Diagnostic yield is a property of the patient cohort and the entire interpretation pipeline, not a fixed attribute of the sequencing platform.

Economic realities: sequential testing versus first-tier WES

The cost of whole exome sequencing in pediatrics cannot be assessed by comparing the price of one laboratory order with the price of another. The relevant unit is the complete diagnostic pathway.

A sequential model may begin with a targeted panel, proceed to WES after a negative result, and then require confirmation, family testing, copy number analysis, functional assays, or specialist reinterpretation. Each stage adds laboratory cost, administrative time, specimen handling, and delay in reaching a clinically actionable conclusion.

In the comparative cohort, a WES-only strategy produced reported savings of approximately $300 to $950 per patient compared with sequential panel-then-WES testing. The range depended on diagnostic yield and the structure of the testing pathway. This does not establish a universal price for WES. Laboratory charges, payer rules, trio availability, confirmatory testing, and regional pricing differ substantially.

The economic calculation changes when a panel provides a rapid answer in a highly selected phenotype. In that setting, a panel may prevent unnecessary broad analysis and reduce the number of variants requiring interpretation. The cheapest assay per order is not automatically the least expensive diagnostic strategy.

Turnaround time is a clinical variable

Genetic testing turnaround time pitfalls are often treated as administrative problems. In pediatric immunology, they can alter clinical management. A prolonged period without a molecular diagnosis may delay eligibility assessment for hematopoietic stem cell transplantation, targeted treatment, infection prophylaxis, family testing, or reproductive counseling.

However, assay breadth alone does not determine turnaround time. Delays can occur at several points:

1. Pre-analytical stage: incomplete phenotype information, poor specimen documentation, or failure to establish parental availability.

2. Laboratory stage: batching, low-quality DNA, repeat sequencing, or confirmation of candidate variants.

3. Interpretive stage: multiple plausible variants, incomplete phenotype matching, and need for multidisciplinary review.

4. Post-analytical stage: segregation testing, functional assays, copy number confirmation, or reclassification.

A narrow panel may generate fewer candidates and therefore a simpler interpretation workflow. WES may require more analysis but can avoid a second test after a negative panel. The correct comparison is total time to a clinically usable result, not only advertised laboratory processing time.

Trio sequencing changes interpretation quality

When parental samples are available, trio WES can improve variant interpretation. De novo variants, recessive inheritance, compound heterozygosity, X-linked transmission, and segregation patterns are easier to evaluate with family data than with a proband-only assay.

This does not eliminate uncertainty. A de novo variant can still be a VUS. A recessive diagnosis can remain unresolved if one allele is detected and the second allele lies in a poorly covered region. Family testing can increase confidence, but it does not replace functional evidence or phenotype concordance.

For a child with suspected immune dysregulation, family structure may be as important as assay selection. The requisition should include parental status, consanguinity where clinically relevant, affected relatives, unexplained infant deaths, recurrent infections, autoimmune disease, and known familial variants. A technically excellent assay supplied with a low-resolution phenotype is an inefficient diagnostic instrument.

The VUS problem: detected does not mean pathogenic

Interpreting variants of uncertain significance in children is one of the central hazards of genomic testing. A VUS indicates that the available evidence does not establish whether the variant is pathogenic or benign. It is not a provisional diagnosis.

A VUS may appear plausible because it is rare, located in a conserved region, predicted damaging by computational tools, or found in a gene associated with immune disease. None of these observations alone is sufficient to direct definitive treatment.

Clinical decisions should not be based on a VUS without supporting evidence such as:

• functional assay results demonstrating a relevant biological defect;
• segregation evidence consistent with the expected inheritance model;
• a phenotype with strong gene-disease concordance;
• independent observations of the same variant in affected individuals;
• validated population-frequency data;
• established loss-of-function or gain-of-function mechanisms for the gene;
• a compatible laboratory signature, such as abnormal protein expression or pathway activity.

The distinction is operational. A pathogenic or likely pathogenic variant can support a molecular diagnosis when the phenotype and inheritance model are coherent. A VUS should trigger structured review, not definitive immune-directed treatment.

Functional assays close the gap between sequence and disease

Immunological assays remain necessary when sequencing produces an ambiguous result. Depending on the suspected mechanism, relevant tests may include lymphocyte subset analysis, immunoglobulin quantification, vaccine-specific antibody responses, neutrophil oxidative burst, complement testing, protein expression, cytokine signaling, or pathway-specific functional studies.

Flow cytometry in pediatrics is particularly useful when interpreted against age-appropriate reference intervals. A low or high cell subset is not independently diagnostic. Sample age, infection status, corticosteroid exposure, recent vaccination, laboratory platform, and reference population influence interpretation.

The same principle applies to molecular biomarkers. A sequence variant becomes more clinically informative when it aligns with a reproducible abnormality in the implicated pathway. Conversely, a discordant functional profile should weaken confidence in a sequence-only interpretation.

Reanalysis is part of the test lifecycle

A negative or uncertain result is not necessarily final. Gene-disease associations expand, variant databases are updated, and classification frameworks change. WES has an advantage over a narrow panel in this setting because the original data may contain relevant genes that were not recognized as clinically important at the time of initial analysis.

Reanalysis should not be treated as an automatic substitute for appropriate first-line testing. It requires a defined trigger: new clinical features, publication of a relevant gene-disease association, a revised variant classification, or a change in the suspected inheritance model. The laboratory and treating team must also distinguish genuine reinterpretation from repeating the same analysis without new evidence.

Strategic selection: when targeted coverage is preferable

The clinical utility of targeted gene panels is highest when the phenotype is well characterized and the panel has been validated for the relevant genes and variant classes. A panel can be the more efficient first test when:

• the suspected immune defect has a narrow differential;
• the gene list is current and includes relevant newly established genes;
• the laboratory provides reliable coverage metrics;
• rapid analysis is clinically important;
• the expected variant types are well detected by the platform;
• the result will directly inform confirmatory functional testing.

Panel selection should not rely on the number of genes alone. A large panel with inconsistent coverage can be less useful than a smaller assay with strong validation. The laboratory should document whether it detects single-nucleotide variants, small indels, exon-level deletions or duplications, mosaicism, and relevant mitochondrial or X-linked variants where applicable.

The following parameters determine whether a panel is fit for purpose:

• gene content and date of last update;
• minimum and mean read depth;
• proportion of coding bases meeting the laboratory’s quality threshold;
• coverage of difficult exons and pseudogene-adjacent regions;
• copy number and structural variant capability;
• confirmation requirements for reportable variants;
• policy for VUS reporting;
• availability of parental or familial testing;
• reanalysis policy after a negative result.

A panel is not “targeted” in the clinical sense if the target list is selected without reference to the child’s phenotype. Targeting is useful only when the hypothesis is strong enough to justify narrowing the search.

When WES should move earlier in the pathway

WES is more defensible as a first-tier or early second-tier test when the case is genetically heterogeneous or does not fit a conventional immune deficiency category. This includes children with combined infection, autoimmunity, inflammation, malignancy susceptibility, developmental abnormalities, and unexplained laboratory findings.

WES also reduces the risk of repeated narrow testing. If the pretest differential already includes multiple immune pathways, ordering several panels sequentially can create duplicated coverage, cumulative cost, and a longer diagnostic timeline. The reported $300–$950 savings for a WES-only strategy in the comparative analysis illustrates this pathway effect.

A broad test is not automatically the correct test in an unstable clinical situation. If a child requires urgent management, treatment should follow the immunological and clinical data available. Genetic sequencing is not a replacement for flow cytometry, functional immune assays, microbiological investigation, or assessment of secondary immune suppression.

The selection logic can be stated compactly:

1. Use a targeted panel when the phenotype sharply narrows the candidate gene set and the panel has validated coverage for the expected variant classes.

2. Use WES earlier when the phenotype is atypical, the differential spans multiple immune pathways, or repeated panel testing is likely.

3. Add family samples whenever possible to improve inheritance analysis and variant interpretation.

4. Escalate beyond WES when the suspected mechanism involves deep non-coding variation, complex structural variation, repeat-associated disease, or a poorly covered genomic region.

5. Pair molecular results with immunological biomarkers and functional assays before assigning clinical causality.

Clinical utility is the final metric

The comparison between exome sequencing and panel testing for pediatric immunodeficiency should end with clinical utility, not with the largest diagnostic-yield percentage. A molecular result is useful when it explains the phenotype, matches the inheritance model, survives technical review, and changes management or family counseling.

Targeted panels provide analytical depth and focused interpretation. WES provides breadth, flexibility, and greater utility for atypical or genetically heterogeneous presentations. The reported data support both approaches: a 56% panel yield in a large suspected PID cohort, an additional 18 diagnoses after WES, and a 45% yield for WES-only analysis in atypical cases. These figures define performance in specific populations. They do not establish a universal hierarchy.

The principal pitfalls are predictable:

• treating panel size as a proxy for sensitivity;
• treating WES as comprehensive genomic testing;
• comparing diagnostic yields across non-equivalent cohorts;
• ignoring variant class and coverage limitations;
• using a VUS as a treatment diagnosis;
• separating sequencing from functional immunology;
• measuring turnaround time per assay rather than time to a clinically actionable result.

For a child with suspected inborn error of immunity, the technically appropriate test is the one that matches the phenotype, inheritance model, and suspected variant architecture. Panel testing and WES are complementary diagnostic strategies. Their value depends on assay design, laboratory quality, interpretation discipline, and integration with pediatric immunological evidence.